BenevolentAI lays off around 180 staffers, cuts pipeline programs in reorg
London-based AI drug discovery company BenevolentAI is laying off about 180 employees as part of a restructuring plan that resulted from a strategic review.
By slashing the headcount, reducing its lab footprint and halting certain drug programs, BenevolentAI hopes to free up more than $55 million (£45 million) and extend the cash runway from Q4 2024 into July 2025, even without new revenue. Amid the changes, CFO Nicholas Keher has also resigned.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
